查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1470903

癌症药物市场：按适应症、药物类别、给药途径、分销和最终用途 - 2024-2030 年全球预测

Oncology Drugs Market by Indication (Bladder Cancer, Breast Cancer, Cervical Cancer), Drug Class (Chemotherapy, Hormonal Therapy, Immunotherapy), Route of Administration, Distribution, End-use - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年癌症治疗市场规模为1,757.8亿美元，2024年达1,884.1亿美元，预计2030年将达2,944.2亿美元，复合年增长率为7.64%。

癌症药物是用于治疗、诊断和预防癌症的特殊药物。这些药物透过各种作用机制靶向癌细胞，因此在恶性的治疗中至关重要。癌症治疗药物分为多种类型，包括化疗、标靶治疗、免疫疗法、荷尔蒙疗法等，每种药物在癌症治疗中都扮演着独特的角色。全球癌症发生率的快速上升，加上抗癌药物开发的投资和政府资助的增加，正在推动市场成长。然而，新药的开发、测试和获得核准的成本对製造商构成了重大挑战。此外，基因组定序技术和生物技术的进步，以及对个人化药物的需求不断增加，正在为市场成长创造利润丰厚的机会。

主要市场统计
基准年[2023] 1757.8亿美元
预测年份 [2024] 1884.1亿美元
预测年份 [2030] 2944.2亿美元
复合年增长率（%） 7.64%

由于药物类别的高精度和较少的副作用，标靶治疗变得越来越重要

化疗涉及使用细胞毒性药物来杀死癌细胞或阻止它们生长。化疗是最古老的癌症治疗方法之一，用于治疗多种类型的癌症。对于晚期癌症或已扩散的癌症，化疗通常是首选。化疗可以单独使用，也可以与其他治疗方法合併使用。荷尔蒙疗法透过阻止身体产生荷尔蒙的能力并阻止其作用来减缓或阻止荷尔蒙敏感肿瘤的生长。这种疗法主要用于乳癌和摄护腺癌，这些癌症通常会随着荷尔蒙的反应而生长。免疫疗法增强人体对抗癌症的自然防御能力。免疫疗法使用体内或实验室製造的物质来增强和恢復免疫系统功能。对于具有表明可能对这种治疗有反应的标记的癌症，例如黑色素瘤、肺癌和肾癌，免疫疗法是首选。标靶治疗针对有助于癌症生长和存活的特定基因、蛋白质或组织环境。这种治疗方法可以阻止癌细胞生长和扩散，同时限制对健康细胞的伤害。标靶治疗特别适用于具有这些药物可以针对的基因突变的癌症，例如某些类型的肺癌、乳癌和大肠癌。

最终用途癌症诊所的扩张加速了对癌症药物的需求

家庭医疗保健对癌症药物的需求显着增加。患者及其家人通常会发现居家医疗更加舒适，并减少了经常去医院带来的心理压力。医院是癌症药物管理的重要终点，尤其是需要先进基础设施和密切医疗监测的治疗。该医院治疗多种癌症，并且经常治疗需要住院治疗的严重病例。癌症诊所位于居家医疗和医院之间，在门诊环境中提供专门护理。这些诊所对于癌症患者的持续治疗和监测至关重要，并且通常可以轻鬆获得最新药物和临床试验。

区域洞察

受高医疗保健支出、强大的研发基础设施和大型製药公司的强大影响力，美洲地区是癌症药物的主要市场。新型药物输送系统和标靶治疗的专利凸显了该国的创新，而对癌症研究和倡议的大量投资则强调了我们对根除癌症的承诺。欧洲市场的特点是统一的监管环境，为癌症药物的开发和核准创造了有利的环境。该市场因成员国之间的价格敏感性而有所不同，需要创新的治疗方法以及具有成本效益的癌症治疗解决方案。中东和非洲地区呈现出多元化的市场环境，波湾合作理事会（GCC）国家对创新癌症治疗表现出较高的购买力，而撒哈拉以南非洲国家则强调可近性和可负担性。在中阶不断壮大、医疗保健支出不断增加以及政府旨在改革医疗保健的倡议的推动下，亚太地区的癌症药物市场正在迅速扩张。亚太地区国家在癌症研究和开发中发挥关键作用，在国内和全球癌症市场上取得了长足的进展。

FPNV定位矩阵

FPNV定位矩阵对于评估癌症药物市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对癌症治疗市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.癌症治疗药物市场的市场规模与预测为何？

2.在癌症药物市场的预测期间内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.癌症药物市场的技术趋势和法规结构是什么？

4.癌症治疗药物市场主要厂商的市场占有率为何？

5.进入抗癌药物市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球癌症发生率正在迅速增加
      • 增加对癌症药物开发的投资和政府资助
      • 扩大个人化医疗的研究与开发
    • 抑制因素
      • 精准医学治疗相关的高成本
    • 机会
      • 基因组序列分析技术和生物技术的进展
      • 生物标记主导药物开发的进展
    • 任务
      • 严格的监管要求和药物开发的复杂性
  • 市场区隔分析
    • 药物类别：由于准确性和副作用较少，标靶治疗变得越来越重要
    • 最终用途：癌症诊所的持续扩张加速了癌症药物的需求
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章以适应症分類的癌症治疗药物市场

  • 膀胱癌
  • 乳癌
  • 子宫颈癌
  • 大肠直肠癌
  • 食道癌
  • 肾癌
  • 肝癌
  • 肺癌
  • 摄护腺癌
  • 胃癌

第七章按药物类别分類的癌症药物市场

  • 化疗
  • 荷尔蒙疗法
  • 免疫疗法
  • 标靶治疗

第八章癌症药物市场：依途径

  • 静脉
  • 口服
  • 话题

第九章 癌症治疗药物市场经销商

  • 线下药局
  • 网路药房

第十章癌症药物市场：依最终用途分类

  • 家庭保健
  • 医院
  • 癌症专科诊所

第11章：美洲的癌症药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章 亚太地区抗癌药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲的癌症药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FDA核准XTANDI 用于高风险前列腺癌治疗
    • 武田製药的 FRUZAQLA 获得 FDA核准用于治疗转移性大肠癌
    • FDA核准武田製药的 FRUZAQLA，一种治疗转移性大肠直肠癌的新疗法
  • 战略分析和建议

第15章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-434CCDA05255

[194 Pages Report] The Oncology Drugs Market size was estimated at USD 175.78 billion in 2023 and expected to reach USD 188.41 billion in 2024, at a CAGR 7.64% to reach USD 294.42 billion by 2030.

Oncology drugs are specialized pharmaceutical agents used in the treatment, diagnosis, and prevention of cancer. These drugs are pivotal in the management of malignancies as they target cancer cells with various mechanisms of action. Oncology drugs can be categorized into several types, including chemotherapy, targeted therapy, immunotherapy, hormonal therapy, and others, each playing a unique role in oncology care. The surging prevalence of cancer worldwide, coupled with the increase in investments and government funding in the development of cancer drugs, propel the market growth. However, the cost of developing, testing, and securing regulatory approval for new drugs poses a significant challenge to the manufacturers. Furthermore, advancements in genomic sequencing technologies and biotechnology, along with the growing need for personalized medicines, create lucrative opportunities for market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 175.78 billion
Estimated Year [2024] USD 188.41 billion
Forecast Year [2030] USD 294.42 billion
CAGR (%) 7.64%

Drug Class: Growing significance of targeted therapy due to its precision and lower side effects

Chemotherapy involves the utilization of cytotoxic drugs to kill or hamper the growth of cancer cells. It is among the oldest forms of cancer treatment and can be used across various cancer types. Chemotherapy is often preferred for advanced cancers or cancers that have metastasized. It can be used as a sole treatment & in combination with other therapies. Hormonal therapy slows or prevents the growth of hormone-sensitive tumors by stopping the body's ability to produce hormones & by interfering with hormone action. This therapy is primarily used for breast and prostate cancers, which often grow in response to hormones. Immunotherapy boosts the body's natural defenses to combat cancer. It utilizes substances made by the body or in a laboratory to enhance and restore immune system function. Immunotherapy is preferred for cancers that have markers indicating they may respond to this treatment, such as melanoma, lung cancer, and kidney cancer. Targeted therapy targets the specific genes, proteins, or the tissue environment contributing to cancer growth and survival. This type of therapy stops the growth and prevalence of cancer cells while limiting damage to healthy cells. Targeted therapy is specifically used for cancers with genetic mutations that can be targeted with these drugs, such as certain types of lung, breast, and colorectal cancers.

End-use: Ongoing expansion of specialty cancer clinics accelerating the demand for oncology drugs

Home healthcare has seen a significant uptick in the demand for oncology drugs, attributed largely to the increasing preference for at-home treatments. Patients and families often find home healthcare options more comfortable, reducing the psychological stress associated with frequent hospital visits. Hospitals remain a critical endpoint for the administration of oncology drugs, especially for treatments that require advanced infrastructure and close medical supervision. They cater to a wide spectrum of cancers, often dealing with more severe cases that necessitate in-patient care. Specialty cancer clinics offer a middle ground between home healthcare and hospitals, providing specialized care in an outpatient setting. These clinics are pivotal for the ongoing treatment and monitoring of cancer patients, often facilitating access to the latest drugs and clinical trials.

Regional Insights

The American region represents a major market for oncology drugs, driven by high healthcare expenditure, robust research and development infrastructure, and a strong presence of leading pharmaceutical companies. Patents in novel drug delivery systems and targeted therapies highlight the country's innovation, while significant investment in cancer research & initiatives underscores a commitment to combating cancer. The European market is marked by a harmonized regulatory landscape that fosters a conducive environment for oncology drug development and approval. Differentiated by price sensitivity across member states, the market demands cost-effective oncology solutions alongside innovative therapies. The Middle East & Africa region presents a diverse market landscape, with Gulf Cooperation Council (GCC) countries showing high purchasing power for innovative oncology treatments, contrasted with Sub-Saharan Africa's focus on accessibility and affordability. The APAC region's oncology drugs market is rapidly expanding, fueled by a growing middle class, increased healthcare spending, and government initiatives aimed at healthcare reform. The APAC countries with significant players in oncology research and development are making strides in both the domestic and global oncology markets.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Oncology Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Oncology Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Oncology Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agenus Inc., Amgen Inc., Aspen Pharmacare Holdings Limited, Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BeiGene, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Debiopharm International SA, Eli Lilly and Company, EMD Serono, Inc. by Merck KGaA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Pfizer Inc., Puma Biotechnology, Inc., Shorla Pharma Ltd., Sun Pharmaceutical Industries Ltd., Sutro Biopharma, Inc., Takeda Pharmaceutical Company Limited, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Oncology Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Indication
    • Bladder Cancer
    • Breast Cancer
    • Cervical Cancer
    • Colorectal Cancer
    • Esophagus Cancer
    • Kidney Cancer
    • Liver Cancer
    • Lung Cancer
    • Prostate Cancer
    • Stomach Cancer
  • Drug Class
    • Chemotherapy
    • Hormonal Therapy
    • Immunotherapy
    • Targeted Therapy
  • Route of Administration
    • Intravenous
    • Oral
    • Topical
  • Distribution
    • Offline Pharmacies
      • Hospital Pharmacies
      • Retail Pharmacies
    • Online Pharmacies
  • End-use
    • Home Healthcare
    • Hospitals
    • Specialty Cancer Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Oncology Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Oncology Drugs Market?

3. What are the technology trends and regulatory frameworks in the Oncology Drugs Market?

4. What is the market share of the leading vendors in the Oncology Drugs Market?

5. Which modes and strategic moves are suitable for entering the Oncology Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surging prevalence of cancer across the globe
      • 5.1.1.2. Increase in investments and government funding in development of cancer drugs
      • 5.1.1.3. Growing research & development in personalized medicines
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with the precision medicine therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in genomic sequencing technologies and biotechnology
      • 5.1.3.2. Development of biomarker-driven drug development
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements and the complexity of drug development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Growing significance of targeted therapy due to its precision and lower side effects
    • 5.2.2. End-use: Ongoing expansion of specialty cancer clinics accelerating the demand for oncology drugs
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Oncology Drugs Market, by Indication

  • 6.1. Introduction
  • 6.2. Bladder Cancer
  • 6.3. Breast Cancer
  • 6.4. Cervical Cancer
  • 6.5. Colorectal Cancer
  • 6.6. Esophagus Cancer
  • 6.7. Kidney Cancer
  • 6.8. Liver Cancer
  • 6.9. Lung Cancer
  • 6.10. Prostate Cancer
  • 6.11. Stomach Cancer

7. Oncology Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Hormonal Therapy
  • 7.4. Immunotherapy
  • 7.5. Targeted Therapy

8. Oncology Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Topical

9. Oncology Drugs Market, by Distribution

  • 9.1. Introduction
  • 9.2. Offline Pharmacies
  • 9.3. Online Pharmacies

10. Oncology Drugs Market, by End-use

  • 10.1. Introduction
  • 10.2. Home Healthcare
  • 10.3. Hospitals
  • 10.4. Specialty Cancer Clinics

11. Americas Oncology Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Oncology Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Oncology Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. FDA Approves XTANDI for High-Risk Prostate Cancer Management
    • 14.3.2. Takeda's FRUZAQLA Receives FDA Approval for Metastatic Colorectal Cance
    • 14.3.3. FDA Approves Takeda's FRUZAQLA, a Novel Treatment for Metastatic Colorectal Cancer
  • 14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. ONCOLOGY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ONCOLOGY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ONCOLOGY DRUGS MARKET DYNAMICS
  • FIGURE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ONCOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ESOPHAGUS CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ESOPHAGUS CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CANCER CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CANCER CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 79. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 80. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 87. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 88. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 91. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 92. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 93. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 94. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 95. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 96. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 99. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 100. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 101. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 102. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 103. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 104. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 105. CANADA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 106. CANADA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 107. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 108. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 109. CANADA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 110. CANADA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 111. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 112. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 113. CANADA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 114. CANADA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 115. CANADA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 116. CANADA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 117. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 118. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 119. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 120. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 121. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 122. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 123. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 124. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 125. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 126. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 127. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 128. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 129. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 130. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 131. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 132. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 133. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 134. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 135. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 136. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 137. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 138. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 139. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 140. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 141. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 142. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 158. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 160. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 162. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 163. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 164. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 166. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 167. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 168. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 169. CHINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 170. CHINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 171. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 172. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 173. CHINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 174. CHINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 175. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 176. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 177. CHINA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 178. CHINA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 179. CHINA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 180. CHINA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 181. INDIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 182. INDIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 183. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 184. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 185. INDIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 186. INDIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 187. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 188. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 189. INDIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 190. INDIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 191. INDIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 192. INDIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 193. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 194. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 195. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 196. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 197. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 198. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 199. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 200. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 201. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 202. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 203. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 204. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 205. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 206. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 207. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 208. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 209. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 210. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 211. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 212. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 213. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 214. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 215. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 216. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 217. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 218. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 219. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 220. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 221. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 222. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 223. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 224. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 225. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 226. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 227. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 228. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 230. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 232. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 234. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 236. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 238. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 239. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 240. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 241. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 242. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 243. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 244. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 245. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 246. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 247. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 248. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 249. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 250. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 251. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 252. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 254. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 256. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 258. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 260. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 262. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 263. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 264. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 265. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 266. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 267. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 268. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 269. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 270. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 271. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 272. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 273. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 274. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 275. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 276. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 277. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 278. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 279. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 280. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 281. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 282. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 283. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 284. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 285. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 286. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 287. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 288. THAILAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 289. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 290. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 291. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 292. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 293. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 294. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 295. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 296. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 297. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 298. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 299. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 300. VIETNAM ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 315. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 316. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 317. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 318. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 319. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 320. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 321. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 322. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 323. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 324. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 325. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 326. DENMARK ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 327. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 328. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 329. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 330. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 331. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 332. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 333. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 334. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 335. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 336. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 337. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 338. EGYPT ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 339. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 340. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 341. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 342. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 343. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 344. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 345. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 346. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 347. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2018-2023 (USD MILLION)
  • TABLE 348. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY OFFLINE PHARMACIES, 2024-2030 (USD MILLION)
  • TABLE 349. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 350. FINLAND ONCOLOGY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 351. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 352. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 353. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 354. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 355. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 356. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 357. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2023 (USD MILLION)
  • TABLE 358. FRANCE ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION, 2024-2030 (USD MILLION)
  • TABLE 359. FRANCE ONCOLOGY DRUGS